Prevention of Oxaliplatin-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Feb 21

PMID 35186722

Authors

Siyu Peng

Ariel Fangting Ying

Nicholas Jian Hao Chan

Raghav Sundar

Yu Yang Soon

Aishwarya Bandla

Affiliations

Soon will be listed here.

Abstract

Background: Oxaliplatin-induced peripheral neuropathy (OIPN) has significant clinical impact on the quality of life for cancer patients and is a dose limiting toxicity. Trials studying preventive measures have been inconclusive. A systematic review and meta-analysis were conducted to evaluate the existing pharmacological and non-pharmacological interventions to prevent chronic OIPN.

Methods: Literature databases PubMed-MEDLINE, Embase and Scopus, were searched from 1 Jan 2005 to 08 Aug 2020 and major conferences' abstracts were reviewed for randomized controlled trials that examined the efficacy of any preventive measure for OIPN. The primary outcome measure was the incidence of chronic OIPN with a preventive intervention as compared to placebo or no intervention. The pooled risk ratio and its 95% confidence interval were calculated using a random effects model. A network meta-analysis was conducted to derive indirect evidence of any preventive effect of an intervention against placebo when original trials compared one intervention against another.

Results: Forty-four trials were analyzed describing 29 chemoprotective interventions, including combinations, and 1 non-pharmacological intervention. Ratings were assessed a combination of outcomes with quality assessment using the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework. Of the 30 interventions examined, there were six interventions supporting potential efficacy, 11 interventions with insufficient evidence and 13 interventions not recommended.

Conclusion: Currently, there is insufficient certainty to support any intervention as effective in preventing OIPN. Of note is that most of these studies have focused on pharmacological interventions; non-pharmacological interventions are underexplored. Further research on ways to limit OIPN is needed.

Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=225095, Prospero Registration Number: CRD42021225095.

Citing Articles

Evaluation of Oral Nano-Silymarin Formulation Efficacy in the Prevention of Hand-Foot Syndrome and Neuropathy Induced by XELOX or m-FOLFOX6 Regimens in Metastatic Colorectal Cancer: A Triple-Blinded, Randomized Clinical Trial.

Karbasforooshan H, Rahimi H, Arasteh O, Allahyari A, Varmaghani M, Jannati M Iran J Pharm Res. 2025; 23(1):e152364.

PMID: 40066113 PMC: 11892790. DOI: 10.5812/ijpr-152364.

Dysbiosis-NK Cell Crosstalk in Pancreatic Cancer: Toward a Unified Biomarker Signature for Improved Clinical Outcomes.

Fanijavadi S, Jensen L Int J Mol Sci. 2025; 26(2).

PMID: 39859442 PMC: 11765696. DOI: 10.3390/ijms26020730.

Interaction of the chemotherapeutic agent oxaliplatin and the tyrosine kinase inhibitor dasatinib with the organic cation transporter 2.

Ahmed Eltayeb S, Dressler J, Schlatt L, Pernecker M, Neugebauer U, Karst U Arch Toxicol. 2024; 98(7):2131-2142.

PMID: 38589558 PMC: 11169033. DOI: 10.1007/s00204-024-03742-1.

Summary of evidence on comprehensive healthcare for chemotherapy-induced peripheral neuropathy in cancer patients.

Dan X, He Y, Tian Y, Huang Y, Ren J Support Care Cancer. 2024; 32(4):264.

PMID: 38564034 DOI: 10.1007/s00520-024-08466-7.

Efficacy of Traditional Chinese Medicine Injection in Preventing Oxaliplatin-Induced Peripheral Neurotoxicity: An Analysis of Evidence from 3598 Patients.

Chen Z, Liu Y, Wei Y, Deng L, Zhang Q Evid Based Complement Alternat Med. 2022; 2022:6875253.

PMID: 35911148 PMC: 9337932. DOI: 10.1155/2022/6875253.

References

Di Cesare Mannelli L, Zanardelli M, Failli P, Ghelardini C . Oxaliplatin-induced neuropathy: oxidative stress as pathological mechanism. Protective effect of silibinin. J Pain. 2012; 13(3):276-84. DOI: 10.1016/j.jpain.2011.11.009. View

de Afonseca S, Cruz F, Cubero D, Lera A, Schindler F, Okawara M . Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial. Sao Paulo Med J. 2013; 131(1):35-8. PMC: 10852076. DOI: 10.1590/s1516-31802013000100006. View

Albers J, Chaudhry V, Cavaletti G, Donehower R . Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014; (3):CD005228. PMC: 10891440. DOI: 10.1002/14651858.CD005228.pub4. View

Zanardelli M, Micheli L, Cinci L, Failli P, Ghelardini C, Di Cesare Mannelli L . Oxaliplatin neurotoxicity involves peroxisome alterations. PPARγ agonism as preventive pharmacological approach. PLoS One. 2014; 9(7):e102758. PMC: 4103888. DOI: 10.1371/journal.pone.0102758. View

Loprinzi C, Lacchetti C, Bleeker J, Cavaletti G, Chauhan C, Hertz D . Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020; 38(28):3325-3348. DOI: 10.1200/JCO.20.01399. View

Grothey A, Nikcevich D, Sloan J, Kugler J, Silberstein P, Dentchev T . Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2010; 29(4):421-7. PMC: 3058288. DOI: 10.1200/JCO.2010.31.5911. View

Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes H, Jahn P . Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020; 31(10):1306-1319. DOI: 10.1016/j.annonc.2020.07.003. View

Cheng X, Huo J, Wang D, Cai X, Sun X, Lu W . Herbal Medicine AC591 Prevents Oxaliplatin-Induced Peripheral Neuropathy in Animal Model and Cancer Patients. Front Pharmacol. 2017; 8:344. PMC: 5461429. DOI: 10.3389/fphar.2017.00344. View

Wang W, Lin J, Lin T, Chen W, Jiang J, Wang H . Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007; 12(3):312-9. DOI: 10.1634/theoncologist.12-3-312. View

10.

Ohsawa M, Otake S, Murakami T, Yamamoto S, Makino T, Ono H . Gabapentin prevents oxaliplatin-induced mechanical hyperalgesia in mice. J Pharmacol Sci. 2014; 125(3):292-9. DOI: 10.1254/jphs.14058fp. View

11.

Ciampi de Andrade D, Teixeira M, Galhardoni R, Ferreira K, Braz Mileno P, Scisci N . Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist. 2017; 22(10):1154-e105. PMC: 5634769. DOI: 10.1634/theoncologist.2017-0235. View

12.

Wang D, Wang Z, Chen G, Peng J, Wang W, Deng Y . Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer. Cancer Med. 2019; 9(1):151-159. PMC: 6943144. DOI: 10.1002/cam4.2693. View

13.

Imai S, Koyanagi M, Azimi Z, Nakazato Y, Matsumoto M, Ogihara T . Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms. Sci Rep. 2017; 7(1):5947. PMC: 5519765. DOI: 10.1038/s41598-017-05784-1. View

14.

Lee M, Cho S, Roh K, Chae J, Park J, Park J . Glutathione alleviated peripheral neuropathy in oxaliplatin-treated mice by removing aluminum from dorsal root ganglia. Am J Transl Res. 2017; 9(3):926-939. PMC: 5375987. View

15.

Park S, Lin C, Krishnan A, Goldstein D, Friedlander M, Kiernan M . Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility. Oncologist. 2011; 16(5):708-16. PMC: 3228192. DOI: 10.1634/theoncologist.2010-0248. View

16.

Shigematsu H, Hirata T, Nishina M, Yasui D, Ozaki S . Cryotherapy for the prevention of weekly paclitaxel-induced peripheral adverse events in breast cancer patients. Support Care Cancer. 2020; 28(10):5005-5011. PMC: 7447649. DOI: 10.1007/s00520-020-05345-9. View

17.

Kanat O, Ertas H, Caner B . Platinum-induced neurotoxicity: A review of possible mechanisms. World J Clin Oncol. 2017; 8(4):329-335. PMC: 5554876. DOI: 10.5306/wjco.v8.i4.329. View

18.

Xu K, Cheng W, Hu Z, Shan W . [Effect of Tanshinone IIA in Preventing and Treating Oxaliplatin Induced Peripheral Neuropathy]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2016; 36(5):559-63. View

19.

Lin P, Lee M, Wang W, Yen C, Chao T, Hsiao L . N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: preliminary data. Support Care Cancer. 2006; 14(5):484-7. DOI: 10.1007/s00520-006-0018-9. View

20.

Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y . Evaluation of the effect of compression therapy using surgical gloves on nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: a phase II multicenter study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat. 2016; 160(1):61-67. DOI: 10.1007/s10549-016-3977-7. View